Pure Global
NCT04695769

Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders

The Role of Combined Ribavirin and Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment of Chronic Hepatitis C Non-responders; A Randomized Controlled Trial
Helwan University·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Hepatitis C
Drug/Device/Intervention
Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Helwan University
Location
Cairo, Egypt
Timeline & enrollment
Phase
Phase 4
Start date
Nov 21, 2020
End date
Nov 21, 2021
Enrollment
400 participants
Primary outcome

Achievement of sustained virological response (SVR)

Summary

This study aims to assess the role of ribavirin as an adjuvant to
 sofosbuvir/velpatasvir/voxilaprevir combination in retreatment of chronic hepatitis C with
 previous treatment failure.

ICD-10 classifications
Chronic viral hepatitis CAcute hepatitis CChronic viral hepatitisOther chronic viral hepatitisChronic hepatitis, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04695769
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04695769 through Pure Global AI's free database. This Phase 4 trial is sponsored by Helwan University and is currently Recruiting. The study focuses on Chronic Hepatitis C. Target enrollment is 400 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.